Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE: Eltrombopag in thrombocytopenic MDS or AML
NCT01440374Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial of eltrombopag in Thrombocytopenia (4 arms), sponsored by Novartis. Primary endpoints: Number of Participants With Platelet Response at 8 weeks and Clinically Relevant Thrombocytopenic Events at 12 weeks. Started Sep 2011; status: completed.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT01440374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440374.